About: The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist
Creator	Costantino, Ryan
Source	Elsevier; Medline; PMC
abstract	The U.S. capacity to manufacture key essential medications has diminished. The U.S. pharmaceutical supply chain (USPSC) has diversified and now relies on international sources of active pharmaceutical ingredients and finished drug products (FDPs). Despite years of effort raising concerns about the USPSC, pharmacists and pharmacy technicians continue to spend a substantial amount of time and energy responding to, and mitigating the impact of, medication shortages, drug recalls, and the adverse outcomes related to low-quality medications. The extent of U.S. reliance on foreign sources of medications is largely unknown. Pharmacists do not have a reliable way to determine the country of origin (i.e., source), capacity, or geographic location of pharmaceutical manufacturers, limiting our ability to anticipate challenges or mitigate risks to our Nation’s drug supply. The U.S. Food and Drug Administration’s task of regulating quality and safety is challenging and will likely require additional safeguards and resources. In addition to pharmacists’ engagement, solutions will likely need to leverage a mix of policy, economic incentives, and expanded objective surveillance testing. The U.S. pharmaceutical supply chain is complex, global, and goes beyond FDPs. The 2020 American Pharmacists Association House of Delegates has rightly asserted that “The quality and safety of pharmaceutical and other medical products and the global pharmaceutical and medical product supply chain are essential to the United States national security and public health.” Pharmacy professionals on the front line engage with patients, identify medication-related issues, and engage in drug-procurement decisions. Pharmacists are essential to our nation’s overall health and must be engaged in the development and implementation of strategies to safeguard the USPSC.
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1016/j.japh.2020.07.018
bibo:pmid	32819877
has license	no-cc
sha1sum (hex)	54057f1bffe276bc3c099701fbdbf9f7e74a6a88
schema:url	https://doi.org/10.1016/j.japh.2020.07.018
resource representing a document's title	The U.S. medicine chest: Understanding the U.S. pharmaceutical supply chain and the role of the pharmacist
has PubMed Central identifier	PMC7434313
has PubMed identifier	32819877
schema:publication	J Am Pharm Assoc (2003)
resource representing a document's body	covid:54057f1bffe276bc3c099701fbdbf9f7e74a6a88#body_text
is schema:about of	named entity 'public health' named entity 'The' named entity 'medical products' named entity 'anticipate' named entity 'medications' named entity 'supply chain' named entity 'Delegates' named entity 'medication' named entity 'essential' named entity 'mix' named entity 'safety' named entity 'HOUSE' named entity 'PUBLIC HEALTH' named entity 'OUR' named entity 'PHARMACEUTICAL' named entity 'YEARS' named entity 'IMPLEMENTATION' named entity 'OTHER MEDICAL' named entity 'SHORTAGES' named entity 'NATIONAL SECURITY' named entity 'FINISHED' named entity 'Administration' named entity 'pharmaceutical' named entity 'origin' named entity 'safeguard' named entity 'drug' named entity 'U.S.' named entity 'raising' named entity 'U.S.' named entity 'Food' named entity 'mitigate' named entity 'safety' named entity 'U.S.' named entity 'medical product' named entity 'U.S. Food and Drug Administration' named entity 'active pharmaceutical ingredients' named entity 'U.S.' named entity 'patent' named entity 'U.S.' named entity 'antihypertensive drug' named entity 'ranitidine' named entity 'American Pharmacists Association' named entity 'supply chain' named entity 'medication adherence' named entity 'supply chain' named entity 'inorganic chemicals' named entity 'Department of Veterans Affairs' named entity 'supply chain' named entity 'United States' named entity 'India' named entity 'Medicaid' named entity 'generic drug' named entity 'high-risk' named entity 'Generic Drug' named entity 'heparin' named entity 'MedWatch' named entity 'active pharmaceutical ingredients' named entity 'FDA' named entity 'public health' named entity 'User Fee' named entity 'angiotensin II receptor blocker' named entity 'pharmacist' named entity 'cGMP' named entity 'hypertension' named entity 'pharmaceutical manufacturers' named entity 'U.S. Food and Drug Administration' named entity 'FDA' named entity '2001 anthrax attacks' named entity 'U.S. government' named entity 'U.S.' named entity 'executive order' named entity 'U.S.' named entity 'United States' named entity 'ranitidine' named entity 'Current Good Manufacturing Practice' named entity 'quality control' named entity 'FDA' named entity 'month-to-month' named entity 'raw materials' named entity 'FDA' named entity 'inactive ingredients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software